Small, stable and robust, VHH offer an attractive construct for incorporation as targeting agents in cell therapies.
VHH can also be easily multimerised to meet a variety of therapeutic needs, enabling refined cell targeting and modes of action while also minimising off-target toxicity. Away from the ectodomain, their small size also permits packaging of more sophisticated intracellular signalling domains, supporting the next generation of cell therapies.
VHH in Cell Therapy
Smaller constructs mean more space for multi-specific targeting modules or next-generation signalling domains.
1. Jayaraman J et al. (2020) Ebiomedicine 58: 102931
2. Lamers CH, et al. (2011) Blood 117(1):72-82
3. Ackaert C et al. (2021) Front. Immunol. 12: 632687
4. Desmyter A et al. (1996) Nat Struct Biol 3(9): 803-811
VHH in CAR-T Resources
Publication: AAV delivery of VHH Intrabodies
De Genst et al showcase the AAV delivery and intracellular in vivo expression of Isogenica’s LlamdA™ VHHs in monomeric and bivalent forms. Interestingly, these VHHs display preferences for distinct conformations of their target – phospolamban.
Partnerships at Isogenica
Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.